Mirae Asset Global Investments Co. Ltd. Acquires 9,567 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) by 31.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 39,885 shares of the company’s stock after acquiring an additional 9,567 shares during the period. Mirae Asset Global Investments Co. Ltd. owned about 0.07% of Akero Therapeutics worth $931,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Orion Capital Management LLC bought a new position in shares of Akero Therapeutics during the third quarter valued at $51,000. Miracle Mile Advisors LLC bought a new position in Akero Therapeutics during the third quarter worth $238,000. China Universal Asset Management Co. Ltd. raised its stake in Akero Therapeutics by 352.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,449 shares of the company’s stock worth $151,000 after buying an additional 5,023 shares during the last quarter. Amalgamated Bank raised its stake in Akero Therapeutics by 18.2% during the third quarter. Amalgamated Bank now owns 7,559 shares of the company’s stock worth $382,000 after buying an additional 1,166 shares during the last quarter. Finally, E Fund Management Co. Ltd. raised its stake in Akero Therapeutics by 10.8% during the third quarter. E Fund Management Co. Ltd. now owns 9,428 shares of the company’s stock worth $477,000 after buying an additional 918 shares during the last quarter.

Insider Buying and Selling at Akero Therapeutics

In other Akero Therapeutics news, insider Catriona Yale sold 20,646 shares of the business’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $35.49, for a total value of $732,726.54. Following the transaction, the insider now directly owns 78,415 shares in the company, valued at $2,782,948.35. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, insider Catriona Yale sold 20,646 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $35.49, for a total value of $732,726.54. Following the sale, the insider now owns 78,415 shares of the company’s stock, valued at $2,782,948.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, COO Jonathan Young sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $24.38, for a total transaction of $121,900.00. Following the completion of the sale, the chief operating officer now directly owns 263,306 shares in the company, valued at approximately $6,419,400.28. The disclosure for this sale can be found here. Insiders have sold a total of 100,646 shares of company stock worth $3,319,877 over the last three months. 9.69% of the stock is currently owned by insiders.

Akero Therapeutics Stock Up 1.0 %

AKRO opened at $21.00 on Wednesday. The company has a quick ratio of 29.27, a current ratio of 29.27 and a debt-to-equity ratio of 0.05. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -7.37 and a beta of -0.38. Akero Therapeutics, Inc. has a twelve month low of $11.25 and a twelve month high of $58.38. The company’s 50-day moving average price is $24.76 and its two-hundred day moving average price is $20.98.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Thursday, February 29th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.17). As a group, equities analysts expect that Akero Therapeutics, Inc. will post -4.06 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Bank of America assumed coverage on shares of Akero Therapeutics in a research note on Monday. They set a “neutral” rating and a $30.00 target price for the company. UBS Group lifted their target price on shares of Akero Therapeutics from $39.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, March 5th. Finally, HC Wainwright lifted their target price on shares of Akero Therapeutics from $40.00 to $43.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Akero Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $37.71.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.